Header Navigation

Cancer is one of the leading causes of death worldwide, and surgical tumor resection remains a cornerstone of therapy. In minimally invasive oncological surgery, precise identification of tumor margins is crucial to preserve healthy tissue while ensuring complete tumor removal. Currently, intraoperative assessment relies largely on histopathological analysis, which is time-consuming and does not provide immediate feedback during surgery.

The early detection, prevention and reversal of chronic diseases remain a medical challenge. Lifestyle-associated metabolic disorders, such as obesity, dyslipidaemia and diabetes mellitus, are key drivers of atherosclerotic cardiovascular disease and microvascular complications. These conditions are primed already during the intrauterine period and early childhood.

More than six million people worldwide suffer from severe heart failure. For many, left ventricular assist devices (LVADs) can be lifesaving. However, implantation still carries significant risks, as it usually requires opening the sternum and the use of cardiopulmonary bypass.

Proton beam therapy (PBT) is an emerging and advanced technique for high-precision radiation treatment of cancer patients. Its success is attributable to the fact that proton beams, in contrast to conventional radiation treatment with high-energy photon beams, have a finite range and deposit most of their dose at the end of range, allowing for dose reduction in healthy tissues surrounding the tumor. However, PBT is very sensititive to tissue morphology and anatomical variations that occur during the course of treatment.